Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb

Jun 21 2017

• By Michael Cipriano

FDA entrance sign 2016

Related Content

Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood

Jun 14 2017

Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

May 23 2017

Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says

May 24 2017

Gottlieb Distances Himself From Trump's User-Fee Heavy Budget

May 26 2017

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

May 26 2017

Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill

Jun 20 2017

Gottlieb Talks Activist Role For FDA In Curbing REMS Abuse

Jun 21 2017

Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Nov 28 2016

Related Companies

Merck & Co., Inc.

Additional Topics

United States Drug Approval Standards Rare Diseases FDA Policy Research & Development BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window